Sign in Subscribe
Cancer

Breakthroughs in Cancer Gene Therapy: Lipid Nanoparticles Pave the Way for Advanced Treatments

Strategic Insights

— 2 min read

Lipid nanoparticles, a revolutionary technology, have been rapidly advancing the field of cancer gene therapy. A recent study from Fudan University in Shanghai, China, has highlighted the potential of these nanoparticles in delivering RNA therapeutics, leading to breakthroughs in the treatment of various diseases, including cancer, HIV, and malaria. The research, published in the journal Nanomedicine, has demonstrated the efficacy of lipid nanoparticles in catalyzing advancements in RNA delivery, paving the way for equitable access and tailored treatments for unmet clinical needs.

Key Takeaways:

  • Lipid nanoparticles (LNPs) enable RNA delivery, primarily via intramuscular (IM) injection, and have led to breakthroughs in COVID-19 vaccines, such as the Pfizer-BioNTech and Moderna vaccines.
  • LNPs encapsulate RNA, using ionizable lipids for endosomal escape and PEG-lipids for stability, and have the potential to enhance controlled release and stability through AI-driven innovations and hybrid lipid-polymer systems.
  • Interdisciplinary efforts in chemistry, immunology, and AI are poised to expand RNA therapeutics for genetic disorders, infectious diseases, and precision oncology, and have the potential to accelerate vaccines against HIV and malaria.
  • Innovations like thermostable lyophilized LNPs and biodegradable materials promise improved accessibility and safety, and can be used beyond pandemics for personalized medicine through CRISPR therapies and cancer neoantigen vaccines.
  • Fudan University's research has been peer-reviewed and has concluded that evolving from emergency tools to mainstream platforms, LNPs herald a paradigm shift toward equitable access and tailored treatments for unmet clinical needs.

Statistics:

  • 2025: The year in which this research was published.
  • 1-25: The page numbers of the article "Evolving from emergency tools to mainstream platforms, LNPs herald a paradigm shift toward equitable access and tailored treatments for unmet clinical needs" in the journal Nanomedicine.
  • 2-4 Park Square: The address of Taylor & Francis Ltd, the publisher of Nanomedicine.
  • Oxon, England: The location of Taylor & Francis Ltd.
  • 245: The page number of the news article "Recent Findings from Fudan University Advance Knowledge in Cancer Gene Therapy (Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery)" in Cancer Gene Therapy Week.

Sources:

  • Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery. Nanomedicine, 2025:1-25.
  • Taylor & Francis Ltd, 2-4 Park Square, Milton Park, Abingdon OR14 4RN, Oxon, England.
  • Fudan University, Key Laboratory of Smart Drug Delivery of MOE, School of Pharmacy, Shanghai, People's Republic of China.
  • Runtong Zhang, Aun Raza, Ruonan Lu, Jingyuan Wen, and Wei Wu.
  • Cancer Gene Therapy Week. Recent Findings from Fudan University Advance Knowledge in Cancer Gene Therapy (Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery). September 15, 2025; p 245.

Read more